Literature DB >> 8646430

Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.

H K Ronday1, H H Smits, G N Van Muijen, M S Pruszczynski, R J Dolhain, E J Van Langelaan, F C Breedveld, J H Verheijen.   

Abstract

Proteolytic joint destruction in inflammatory and non-inflammatory arthropathy is believed to be mediated, at least in part, by the plasminogen activation (PA) system. To further investigate possible involvement of the PA system, we quantified immunoreactive urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA), both plasminogen activator inhibitors (PAI-1 and PAI-2) and u-PA-receptor (u-PAR) in synovial tissue extracts of 14 patients with rheumatoid arthritis (RA) and 12 with osteoarthritis (OA). u-PA, PAI-1, PAI-2 and u-PAR concentrations were significantly higher in RA than in OA patients. t-PA antigen levels were significantly lower in RA than in OA synovial tissue extracts. Immunohistochemistry was performed to compare the distribution and staining intensity of these components in samples of RA and OA synovial tissue. Intense immunostaining of u-PA, u-PAR, PAI-1 and, to a lesser degree, PAI-2 was observed predominantly in the synovial lining of RA patients. In OA patients, u-PA, PAI-1, PAI-2 and u-PAR were barely detectable. t-PA immunostaining was restricted to the endothelial side of vascular walls in both groups. We conclude that the observed increase of u-PA, u-PAR and PAI expression, distributed mainly in the synovial lining area of proliferative and invasively growing synovial tissue in RA patients, supports a pathogenic role for the PA system in destructive arthritis. Depressed t-PA-mediated plasminogen activation might contribute to delayed intra-articular fibrin removal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8646430     DOI: 10.1093/rheumatology/35.5.416

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  20 in total

Review 1.  A fibrin based model for rheumatoid synovitis.

Authors:  O Sánchez-Pernaute; R Largo; E Calvo; M A Alvarez-Soria; J Egido; G Herrero-Beaumont
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

Review 2.  Urokinase in rheumatoid arthritis: causal or coincidental?

Authors:  N Busso; A So
Journal:  Ann Rheum Dis       Date:  1997-12       Impact factor: 19.103

3.  Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.

Authors:  N Busso; V Péclat; A So; A P Sappino
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

4.  Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.

Authors:  Z Szekanecz; G K Haines; A E Koch
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

5.  Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-alpha-stimulated gene-6) in murine models of experimental arthritis.

Authors:  T Bárdos; R V Kamath; K Mikecz; T T Glant
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.

Authors:  Selene Pérez-García; Mar Carrión; Rebeca Jimeno; Ana M Ortiz; Isidoro González-Álvaro; Julián Fernández; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Mol Neurosci       Date:  2013-12-07       Impact factor: 3.444

7.  Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.

Authors:  O Slot; N Brünner; H Locht; P Oxholm; R W Stephens
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

8.  Exacerbation of antigen-induced arthritis in urokinase-deficient mice.

Authors:  N Busso; V Péclat; K Van Ness; E Kolodziesczyk; J Degen; T Bugge; A So
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

Review 9.  Advances and challenges in hemophilic arthropathy.

Authors:  Tine Wyseure; Laurent O Mosnier; Annette von Drygalski
Journal:  Semin Hematol       Date:  2015-10-26       Impact factor: 3.851

10.  Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

Authors:  Junjiang Sun; Narine Hakobyan; Leonard A Valentino; Brian L Feldman; R Jude Samulski; Paul E Monahan
Journal:  Blood       Date:  2008-08-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.